Sign up to get free evidence-based articles, exclusive discounts, and insights from industry-leaders.
Email could not be subscribed.
Thank you for signing up!
presented by Todd E. Davenport, PT, DPT, MPH, OCS, Staci Stevens, MA, and Mark VanNess, PhD
Financial: Todd Davenport, Mark VanNess, and Staci Stevens receive compensation from MedBridge for this course. There is no financial interest beyond the production of this course.
Non-Financial: Todd Davenport, Mark VanNess, and Staci Stevens have no competing non-financial interests or relationships with regard to the content presented in this course.
Satisfactory completion requirements: All disciplines must complete learning assessments to be awarded credit, no minimum score required unless otherwise specified within the course.
MedBridge is committed to accessibility for all of our subscribers. If you are in need of a disability-related accommodation, please contact [email protected]. We will process requests for reasonable accommodation and will provide reasonable accommodations where appropriate, in a prompt and efficient manner.
This lesson is the second part of the two-course series. Complete Part One before beginning this course.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) causes severely disabling fatigue within the context of a constellation of unusual signs and symptoms, which are associated with overexertion. Because people with ME/CFS present with a whole host of clinical findings, there are multiple reasons for entry into medical and rehabilitation settings. The multifactorial clinical presentation of ME/CFS emphasizes the need for clinicians to recognize ME/CFS, in order to advocate for patients/clients with possible ME/CFS and to direct its appropriate management. The pathoetiology of ME/CFS is becoming better understood, and there is emerging evidence based on this pathoetiological evidence to support best practices in analeptic management strategies for people with ME/CFS.
This two-part course series provides the opportunity for attendees to receive the latest information in recognition, etiology, and analeptic management of patients with ME/CFS from a panel of established researchers and clinicians. In this session, the presenters will (i) summarize the clinical features ME/CFS with respect to optimal identification and differential diagnosis; (ii) describe the pathoetiology underlying the clinical features of ME/CFS; and (iii) provide an actionable framework for optimal analeptic management of individuals with ME/CFS that is based on current scientific evidence.
Todd E. Davenport, PT, DPT, MPH, OCS
Todd serves as professor and vice-chair of the Department of Physical Therapy in the School of Health Sciences at the University of the Pacific in Stockton, California, where he teaches in the Doctor of Physical Therapy (DPT) program. Todd is a graduate of the University of Southern California's DPT and Orthopedic Physical Therapy Residency programs.…
Read full bioStaci Stevens, MA
Staci Stevens holds a bachelor's degree in Sports Medicine and a master's degree in Exercise Physiology from the University of the Pacific in Stockton, California. Ms. Stevens, in conjunction with Workwell Foundation's research team, pioneered the use of two-day cardiopulmonary exercise testing (CPET) in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) to document the hallmark clinical feature…
Read full bioMark VanNess, PhD
J. Mark VanNess, PhD, is a cardiovascular biologist and Distinguished Professor in the department of Health and Exercise Science at the University of the Pacific. He studied biology, chemistry, and exercise science as an undergraduate student and exercise physiology for his master's degree. He received his doctoral degree from the program in Neuroscience at Florida…
Read full bioEmail could not be subscribed.
Thank you for signing up!
Thank you!
1. Etiological Clues From Cardiopulonary Exercise Testing
Measurements obtained during maximal cardiopulmonary exercise tests (CPET) are commonly used across clinical populations to make determinations regarding cardiac, pulmonary, and metabolic deficits that may underlie disablement, as well as to stratify the severity of functional impairment. Similarly, maximal CPET has been used in people with ME/CFS. The purpose of this chapter is to introduce the learner to inferences that can be made regarding the pathoetiology of disablement in ME/CFS, based on maximal CPET data.
2. Analeptic Strategies for ME/CFS
Clinical management strategies for ME/CFS should be informed by current physiological evidence. Specifically, CPET findings of aerobic system dysfunction suggest that clinical management should emphasize energy conservation self-management strategies and restorative anaerobic activities, as tolerated by the patient. The purpose of this chapter is to describe a staged approach to analeptic management for people with ME/CFS.
More Courses in this Series
Email could not be subscribed.
Thank you for signing up!
For larger groups (25+ seats), request a demo to learn more about solution options and pricing for your organization. For detailed pricing and self-service check-out, visit Plans & Pricing.
Fill out the form below to learn about our solution and pricing for your organization. For other questions or support, visit our contact page.
Fill out the form below to learn about our solution and pricing for your organization. For other questions or support, visit our contact page.
Now Available: Epic MyChart Integration!
Optimize the patient experience by enabling access to MedBridge HEP directly from within MyChart.
Learn More
The Future of Digital MSK Care is Here
MedBridge Pathways, our new digital care platform, is purpose built to bring provider-first, therapy-driven MSK care to patients across the care continuum.
Learn More